- Home
- PCSC vs CHRS Comparison
PCSC vs CHRS Comparison
Compare PCSC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSC
- CHRS
- Stock Information
- Founded
- PCSC 2024
- CHRS 2010
- Country
- PCSC United States
- CHRS United States
- Employees
- PCSC N/A
- CHRS N/A
- Industry
- PCSC
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCSC
- CHRS Health Care
- Exchange
- PCSC NYSE
- CHRS Nasdaq
- Market Cap
- PCSC 114.2M
- CHRS 112.5M
- IPO Year
- PCSC 2024
- CHRS 2014
- Fundamental
- Price
- PCSC $10.70
- CHRS $0.76
- Analyst Decision
- PCSC
- CHRS Buy
- Analyst Count
- PCSC 0
- CHRS 3
- Target Price
- PCSC N/A
- CHRS $4.68
- AVG Volume (30 Days)
- PCSC 6.7K
- CHRS 1.2M
- Earning Date
- PCSC 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- PCSC N/A
- CHRS N/A
- EPS Growth
- PCSC N/A
- CHRS N/A
- EPS
- PCSC N/A
- CHRS N/A
- Revenue
- PCSC N/A
- CHRS $272,251,000.00
- Revenue This Year
- PCSC N/A
- CHRS N/A
- Revenue Next Year
- PCSC N/A
- CHRS $132.69
- P/E Ratio
- PCSC $46.48
- CHRS N/A
- Revenue Growth
- PCSC N/A
- CHRS 19.87
- 52 Week Low
- PCSC $10.02
- CHRS $0.66
- 52 Week High
- PCSC $10.74
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- PCSC N/A
- CHRS 40.60
- Support Level
- PCSC N/A
- CHRS $0.74
- Resistance Level
- PCSC N/A
- CHRS $0.79
- Average True Range (ATR)
- PCSC 0.00
- CHRS 0.05
- MACD
- PCSC 0.00
- CHRS 0.00
- Stochastic Oscillator
- PCSC 0.00
- CHRS 12.76
About PCSC PERCEPTIVE CAP SOLUTIONS CORP
Perceptive Capital Solutions Corp is a blank check company.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.